$PCVX News

Last published 1d ago

1d agoPCVXGUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - VAXCYTE INCEarnings Call TranscriptsAll right. Good afternoon, everybody. Welcome to Guggenheim's Healthcare Innovation Conference. I'm Seamus Fernandez, one of the senior biopharma analysts here at Guggeheim, and I am really pleased to be joined again thi
1w agoPCVXVaxcyte, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
1w agoPCVXVaxcyte Reports Third Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireVAX-31 Adult Indication: Announced Positive Topline Data from OPUS-1 Pivotal Phase 3 Trial; VAX-31 Met All Prespecified Primary Endpoints, Was Well Tolerated and Demonstrated a Safety Profile Similar to PCV20 and PCV21
1mo agoPCVXVaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Convertible Senior NotesGlobeNewswireSAN CARLOS, Calif., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company, announced today the closing of its previously announced concurrent underwritten public
1mo agoPCVXVaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior NotesGlobeNewswireSAN CARLOS, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company, announced today the pricing of concurrent underwritten public offerings of 7,412,500
1mo agoPCVXVAX-31 OPUS-1 Adult Phase 3 Trial: Topline Results Conference Call - VAXCYTE INCEarnings Call TranscriptsGood morning, and welcome to VACCITE's conference call to discuss the Opus 1, Phase 3, Topline Results. Following the prepared remarks, we will open the call for questions. If you would like to ask a question at that tim
2mo agoPCVXVaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline DataGlobeNewswireLuis Jodar, Ph.D., Former Pfizer Chief Medical Officer for Vaccines and Infectious Diseases with Extensive Leadership Experience Across Clinical Development and Medical Affairs for Pneumococcal Conjugate Vaccines
2mo agoPCVXVaxcyte to Participate in Upcoming Investor ConferencesGlobeNewswireSAN CARLOS, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in fireside chats and host
3mo agoPCVXVaxcyte Reports Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireTopline Safety, Tolerability and Immunogenicity Data from VAX-31 Adult Phase 3 OPUS-1 Trial Expected in Fourth Quarter of 2026; OPUS-2 and OPUS-3 Phase 3 Results Expected in First Half of 2027 Topline Safety,
4mo agoPCVXVaxcyte to Participate in Upcoming Investor ConferencesGlobeNewswireSAN CARLOS, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in and host one-on-one meetings
5mo agoPCVXVaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy AdultsGlobeNewswireFirst-in-Human Study Evaluating VAX-A1, a Potential Best-in-Class Vaccine Candidate Designed to Provide Broad Protection Against Disease Caused by Group A Streptococcus Two-Stage, Dose-Escalation Study Designed with
6mo agoPCVXVaxcyte Reports First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireEnrollment Now Completed for OPUS-1, OPUS-2 and OPUS-3 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults Topline Safety, Tolerability and Immunogenicity Data
7mo agoPCVXVaxcyte to Present at the 25th Annual Needham Virtual Healthcare ConferenceGlobeNewswireSAN CARLOS, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in a fireside chat at the 25th
7mo agoPCVX VERAVera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal OfficerGlobeNewswireBRISBANE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious
7mo agoPCVXVaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in AdultsGlobeNewswireOPUS-1 Phase 3 Study Designed to Establish a New Standard for Adult Pneumococcal Conjugate Vaccines (PCVs) Through Head-to-Head Safety, Tolerability and Immunogenicity Comparisons of VAX-31 with Capvaxive® (PCV21)
8mo agoPCVXVaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateGlobeNewswireComprehensive VAX-31 Adult Phase 3 Clinical Program, Finalized in Consultation and Alignment with FDA, Advances with Three Phase 3 Studies Underway to Support Planned BLA Submission Topline Safety, Tolerability and
9mo agoPCVXVaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal VaccinesGlobeNewswireCompany Expects to Report Topline Data from OPUS-3 Trial and OPUS-2 Phase 3 Trial Evaluating Concomitant Administration of VAX-31 and a Seasonal Influenza Vaccine in First Half of 2027 OPUS-1, VAX-31 Adult Phase 3
9mo agoPCVXVaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026GlobeNewswireSAN CARLOS, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company, announced today that it will report financial results for the fourth quarter and full year
9mo agoPCVXVaxcyte to Present at the Guggenheim Emerging Outlook: Biotech SummitGlobeNewswireSAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in a fireside chat at the
9mo agoPCVXVaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewswireSAN CARLOS, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company, announced today the closing of its previously announced underwritten public offering of
9mo agoPCVXVaxcyte Announces Pricing of $550 Million Public OfferingGlobeNewswireSAN CARLOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company, announced today the pricing of an underwritten public offering of common stock. Vaxcyte is
9mo agoPCVXVaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswireSAN CARLOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company, today announced that it has commenced an underwritten public offering of $500,000,000 of
9mo agoPCVXVaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate VaccineGlobeNewswireVAX-31 Adult Indication: Vaxcyte Doses First Participants in Phase 3 Study Evaluating Concomitant Administration of VAX-31 and Seasonal Influenza Vaccine (OPUS-2) and Expects to Initiate Phase 3 Study in Adults
11mo agoPCVXVaxcyte Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in AdultsGlobeNewswireTrial Design Finalized in Consultation and Alignment with U.S. Food and Drug Administration Study Designed to Establish a New Standard for Adult Pneumococcal Conjugate Vaccines Through Head-to-Head Safety, Tolerability
1y agoPCVXVaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding StudyGlobeNewswireFinal Data from VAX-24 Infant Phase 2 Dose-Finding Study Consistent with Previously Reported Positive Interim Data; Provide Additional Evidence Supporting Higher VAX-31 Doses Being Evaluated in Ongoing Infant Phase 2
1y agoPCVXVaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and ServicesGlobeNewswireNew Agreement with Thermo Fisher Scientific Expands Domestic Capacity to Support Future Commercial Manufacturing of Vaxcyte's Broad-Spectrum Pneumococcal Conjugate Vaccine Candidates SAN CARLOS, Calif., Sept. 30, 2025
1y agoPCVXTentarix Biotherapeutics Strengthens Executive TeamBusiness WireTentarix Biotherapeutics LP, a biotechnology company developing best-in-class, targeted and conditionally active multispecific biologics, today announced four key executive changes that further strengthen its executive
1y agoPCVXVaxcyte, Inc. (PCVX) Presents At Cantor Global Healthcare Conference 2025 TranscriptEarnings Call Transcripts
1y agoPCVXVaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized DoseGlobeNewswireVAX-31 Optimized Dose, with Majority of Serotypes Dosed at 4.4mcg and Balance at 3.3mcg, is Designed to Elicit Even Stronger Immune Responses in Infant Population to Protect Against Invasive Pneumococcal Disease (IPD)
1y agoPCVXVaxcyte Reports Second Quarter 2025 Financial Results and Provides Business Update, Highlighting Key Clinical and Regulatory Progress for VAX-31, a Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV)GlobeNewswireFollowing Interactions with FDA on VAX-31 Adult Program, Including End-of-Phase 2 Meeting, Company Finalizing Phase 3 Clinical Program to Validate VAX-31 as Potential New Standard-of-Care Adult PCV; Pivotal,
1y agoPCVXVaxcyte Reports First Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswire-- Company Reported Positive Topline Safety, Tolerability and Immunogenicity Data from Phase 2 Dose-Finding Study of VAX-24 in Healthy Infants; Balance of Data Expected by End of 2025 -- -- Initiated Second and Final
1y agoPCVXVaxcyte Appoints Dr. Olivier Brandicourt to Board of DirectorsGlobeNewswireSAN CARLOS, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today
1y agoPCVXVaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding StudyGlobeNewswire-- At All Doses Evaluated, VAX-24 Was Well-Tolerated and Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20® (PCV20) -- -- At All Doses Evaluated, VAX-24 Elicited Substantial Immune Responses
1y agoPCVXVaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 StudyGlobeNewswireSAN CARLOS, Calif., March 30, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial
1y agoPCVXVaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateGlobeNewswire-- Completed Successful VAX-31 Phase 2 Adult Program; Company Remains on Track to Initiate VAX-31 Adult Phase 3 Pivotal, Non-Inferiority Study by Mid-2025 and Announce Topline Safety, Tolerability and Immunogenicity Data
1y agoPCVXVaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025GlobeNewswireSAN CARLOS, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial
1y agoPCVXVaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in InfantsGlobeNewswire-- Advancement to Stage 2 of Infant Study Supported by Review of Stage 1 Safety and Tolerability Data -- -- Company Expects to Announce VAX-31 Infant Study Topline Safety, Tolerability and Immunogenicity Data from
1y agoPCVXVaxcyte to Present at the Guggenheim SMID Cap Biotech ConferenceGlobeNewswireSAN CARLOS, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial
1y agoPCVXKuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law FirmGlobeNewswireNEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Vaxcyte, Inc. (NASDAQ:PCVX) breached their fiduciary duties to
1y agoPCVXKuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Vaxcyte, Inc. (NASDAQ: PCVX) breached...
1y agoPCVXKuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law FirmGlobeNewswireNEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Vaxcyte, Inc. (NASDAQ:PCVX) breached their fiduciary duties to
1y agoPCVXVaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in InfantsGlobeNewswire-- Company Expects to Announce VAX-31 Infant Study Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series in Mid-2026, Followed by Topline Data from the Booster Dose Approximately Nine
1y agoPCVXVaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult ProgramsGlobeNewswire-- VAX-31 Infant Indication: Investigational New Drug Application Cleared by FDA; Company Expects to Initiate VAX-31 Infant Phase 2 Study by the End of January 2025 -- -- VAX-31 Adult Indication: Breakthrough Therapy
2y agoPCVXVaxcyte Reports Third Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswire-- Company Reported Positive Topline Safety, Tolerability and Immunogenicity Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate, in Adults Aged 50 and Older -- -- PCV Adult
2y agoPCVXVaxcyte to Present at the 2024 Cantor Global Healthcare ConferenceGlobeNewswireSAN CARLOS, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial
2y agoPCVXVaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewswireSAN CARLOS, Calif., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial
2y agoPCVXVaxcyte Announces Pricing of $1.3 Billion Public OfferingGlobeNewswireSAN CARLOS, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial
2y agoPCVXVaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswireSAN CARLOS, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial
2y agoPCVXVaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and OlderGlobeNewswire-- At All Doses Studied, VAX-31 Demonstrated Robust Opsonophagocytic Activity Immune Responses for All 31 Serotypes -- -- At Middle and High Doses, VAX-31 Met or Exceeded Regulatory Immunogenicity Criteria for All 31
2y agoPCVXVaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and OlderGlobeNewswireSAN CARLOS, Calif., Sept. 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial